Clinical Trial Update: Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update evaluating immunotherapy after reduced-intensity conditioning and allogeneic stem cell transplant for poor risk CD30+ Hodgkin Lymphoma p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Snippet

Sponsor: New York Medical College | Conditions: Hodgkin Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN